In WP1, the Task 1.1 State-of-the-Art and Requirements Analysis, Task 1.2 SILICOFCM Specification and Task 1.3 SILICOFCM Reference Architecture are accomplished, contributing to design of the innovative SILICOFCM platform, tools and modules.
In WP2, the experiments for generation of physiological and biochemical data from human FCM samples and mouse models are accomplished, contributing also to the development and testing of computational models in WP5. The Task 2.1 Protein and cell data, Task 2.2 Physiological experiments and Task 2.3 Imaging acquisition data are completed.
In WP3, the retrospective clinical study (Task 3.1) is completed by integrating the anonymised HCM patients datasets from clinical partners, providing insight into cross-sectional demographic, clinical and genetic characteristics. The prospective clinical study (Task 3.2) aiming to evaluate the effect of pharmacological and lifestyle interventions on disease progression and clinical phenotype in HCM patients, and the genetic testing (Task 3.3) are completed, as well as the in vivo and ex vivo investigation of cardiomyopathies in rats (Task 3.4).
In WP4, a reference graph genome (Task 4.1) is created enabling rapid and accurate variant calling. Also, two bioinformatics pipelines for the analysis of the whole exome sequencing/targeted panel sequencing datasets are developed (Task 4.2) as well as the annotation of variant call sets (Task 4.3) called using the developed pipelines. This work contributed to the development of cardiomyopathy risk stratification system (Task 4.4).
In WP5, MUSICO platform is upgraded in order to trace the effect of the sarcomeric proteins mutations and precisely follow the implications of structural and kinetics changes of mutated proteins along multi-scales (Task 5.1) covering the data integration from different experimental setups. The upgraded FE biomechanical solvers PAK and Alya (Task 5.2) enable solving tightly coupled FS, electro-mechanic and ionic/drug transport simulations of the human heart. The linking of MUSICO and FE solvers (Task 5.4) has been followed by their continuous and parallel upgrades. The extraction of genetic data that serve as input to MUSICO simulations (Task 5.3) is accomplished.
In WP6, Development of virtual patients models repository (Task 6.1) Generation and visualization of virtual heart FCM cohorts (Task 6.2) and Predictive modelling using data mining algorithms (Task 6.3) are accomplished, developing the i) plausible virtual patients multi-repository for SILICOFCM tools, and ii) disease progression tool. The testing, evaluation, model validation and optimization are completed (Task 6.4).
In WP7, Integration in the cloud platform (Task 7.1) and Design and implementation of standard interconnection between systems (Task 7.2) are accomplished. The SILICOFCM platform is refined (Task 7.3) and MCDM tool has been integrated (Task 7.4).
In WP8, the activities related to Development workflow assistant for EMA/FDA approval (Task 8.1) Set up of R&D computation pipelines for drug testing (Task 8.2) Interface for drug database (Task 8.3) and Development of report tool (Task 8.4) are accomplished.
In WP9, successful dissemination and communication of project’s results through various channels attracted the identified stakeholders and raised awareness of SILICOFCM project. The exploitation plan is finalized, as well as the business plan for the project’s exploitable products.
In WP10, the administrative and financial management including quality control and DMP is accomplished.
In W11, the ethical requirements are followed though project lifetime
